FibroGen posts Q3 net income of $200.6 mln after sale of China operations

Kyntra Bio

10/11/2025 21:14

Overview

FibroGen Q3 net income $200.6 mln, driven by sale of China operations

Revenue from continuing operations in Q3 was $1.1 mln, up from $0.1 mln in Q3 2024

Company expects cash to fund operations into 2028

Outlook

FibroGen expects cash resources to fund operations into 2028

Interim results from FG-3246 trial expected in second half of 2026

FibroGen to submit Phase 3 roxadustat protocol in 4Q 2025

Result Drivers

CHINA OPERATIONS SALE - Sale of FibroGen China to AstraZeneca for $220 mln simplified capital structure and extended cash runway

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
$200.64 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for FibroGen Inc is $43.00, about 74.3% above its November 7 closing price of $11.03

Press Release: ID:nGNXbPD220

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)